Ninaad Lasrado, PhD
@ninaadlasrado.bsky.social
Postdoc @BarouchLab/ @harvardmed/@BIDMChealth | Ph.D @unlincoln | Interested in mRNA therapeutics, mucosal immunity, and bioengineering vaccines for infectious diseases
#longcovid or PASC may be characterized by persistent activation of chronic inflammatory pathways, affecting millions of Americans. Our latest #clinical trial focuses on repurposing Abrocitinib to reduce symptoms in people with #LongCOVID. (1/2)
March 29, 2025 at 1:30 AM
#longcovid or PASC may be characterized by persistent activation of chronic inflammatory pathways, affecting millions of Americans. Our latest #clinical trial focuses on repurposing Abrocitinib to reduce symptoms in people with #LongCOVID. (1/2)